List view / Grid view
30 March 2016 | By Victoria White
Howard B. Rosen has been appointed the Chief Executive Officer of AcelRx. The company has also selected ARX-04 as its primary focus for clinical development...
26 February 2016 | By Victoria White
The safety and efficacy profile observed in the Phase III study is consistent with previous trial results for ARX-04...
6 October 2015 | By Victoria White
AcelRx is developing ARX‑04 for the management of moderate-to-severe acute pain in a variety of medically supervised settings, including the emergency room...
22 September 2015 | By Victoria White
Zalviso is designed to offer sustained (for up to 72 hours) pain relief for acute moderate-to-severe post-operative pain...
15 May 2015 | By Victoria White
AcelRx Pharmaceuticals has entered into a contract to develop ARX-04 worth up to $17.0 million, supported by the US Department of Defence (DoD)...
